PA8816401A1 - Patente de invencion de una vacuna multicomponente o monocomponente para ser utilizada contra la enfermedad de chagas, composiciones farmacéuticas que las contienen, procedimiento para la obtención del inmunógeno que las contienen, procedimiento para - Google Patents
Patente de invencion de una vacuna multicomponente o monocomponente para ser utilizada contra la enfermedad de chagas, composiciones farmacéuticas que las contienen, procedimiento para la obtención del inmunógeno que las contienen, procedimiento paraInfo
- Publication number
- PA8816401A1 PA8816401A1 PA20098816401A PA8816401A PA8816401A1 PA 8816401 A1 PA8816401 A1 PA 8816401A1 PA 20098816401 A PA20098816401 A PA 20098816401A PA 8816401 A PA8816401 A PA 8816401A PA 8816401 A1 PA8816401 A1 PA 8816401A1
- Authority
- PA
- Panama
- Prior art keywords
- championship
- cruzi
- procedure
- vaccine
- chagas disease
- Prior art date
Links
- 229960005486 vaccine Drugs 0.000 title abstract 6
- 230000002163 immunogen Effects 0.000 title abstract 4
- 206010001935 American trypanosomiasis Diseases 0.000 title abstract 3
- 208000024699 Chagas disease Diseases 0.000 title abstract 3
- 241000223109 Trypanosoma cruzi Species 0.000 title abstract 3
- 238000000034 method Methods 0.000 title abstract 3
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- 241000223104 Trypanosoma Species 0.000 abstract 3
- 229920001184 polypeptide Polymers 0.000 abstract 3
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 3
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 3
- 244000045947 parasite Species 0.000 abstract 2
- 210000001744 T-lymphocyte Anatomy 0.000 abstract 1
- 239000002253 acid Substances 0.000 abstract 1
- 230000028993 immune response Effects 0.000 abstract 1
- 208000015181 infectious disease Diseases 0.000 abstract 1
- 230000007923 virulence factor Effects 0.000 abstract 1
- 239000000304 virulence factor Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/002—Protozoa antigens
- A61K39/005—Trypanosoma antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/002—Protozoa antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55505—Inorganic adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55522—Cytokines; Lymphokines; Interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55522—Cytokines; Lymphokines; Interferons
- A61K2039/55527—Interleukins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Tropical Medicine & Parasitology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
EL OBJETO PRINCIPAL DE LA PRESENTE INVENCION ES UNA VACUNA CONTRA LA ENFERMEDAD DE CHAGAS, CAPAZ DE ESTIMULAR LA RESPUESTA INMUNE CONTRA EL FACTOR DE VIRULENCIA TRANS-SIALIDASA DEL PARÁSITO TRYPANOSOMA CRUZI, CARACTERIZADA DICHA VACUNA PORQUE COMPRENDE UNA VACUNA MULTICOMPONENTE PARA LA ENFERMEDAD DEL CHAGAS (TRIPANOSOMIASIS AMERICANA) CARACTERIZADA PORQUE COMPRENDE: (1) UNA PORCIÓN INMUNÓGENICA CONFORMADA POR UNO O MÁS POLIPEPTIDOS RECOMBINANTES O SINTETICOS, O FRACCIONES DE ELLOS, Y (B) UNO O MAS POLINUCLEOTIDOS QUE COMPRENDEN A LAS REGIONES QUE CODIFICAN A UNO O MAS POLIPEPTIDOSINMUNOGENICOS, AMBAS PORCIONES PARA LOS DERIVADOS DE LOS TRYPANOSOMA CRUZI ( ES DECIR DE UN T. CRUZI Y/O UNA REGION CONSERVADA COMUN A VARIOS DE ELLOS) DONDE LA ADMINISTRACION DE DICHA VACUNA PROTEGE DE LA INFECCION DEL PARASITO, LO ELIMINA O ATENUA LAS CONSECUENCIAS CLINICAS DE DICHA INFECCION. OTRO OBJETO DE LA PRESENTE INVENCION ES UNA VACUNA MONOCOMPONENTE PARA LA ENFERMEDAD DE CHAGAS QUE COMPRENDE AL MENOS UN COMPONENTE SELECCIONADO ENTRE UNA PORCION INMUNOGENICA CONFORMADA POR UNO O MAS POLIPEPTIDOS RECOMBINANTES O SINTETICOS, O FRACCIONES DE ELLOS Y UN GRUPO DE POLINUCLEOTIDOS QUE COMPRENDEN A LAS REGIONES QUE CODIFICAN A UNO O MAS POLIPEPTIDOS INMUNOGENICO DERIVADOS DE LOS TRYPANOSOMA CRUZI ( ES DECIR DE UN T, CRUZI Y/O UNA REGION CONSERVADA COMUN A VARIOS DE ELLOS), DONDE LA PORCION INMUNOGENICA O EL GRUPO DE POLINUCLEOTIDO ESTIMULA UNA RESPUESTA DE ANTICUERPOS, DE CELULAS T CD4+SESGADAS TH1 O T CD8+ CONTRA EL TRIPANOSOMA CRUZI. TAMBIEN SE INCLUYEN EN LA PRESENTE INVENCION LAS COMPOSICIONES FARMACEUTICAS QUE CONTIENEN DICHAS VACUNAS MULTICOMPONENTES Y MONOCOMPONENTES, PROCEDIMIENTOS PARA LA OBTENCION DE LA PORCION INMUNOGENA DE DICHAS VACUNAS Y EL ACIDO NUCLEICO UTILIZADO EN DICHO PROCEDIMIENTO.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| ARP070104827A AR064593A1 (es) | 2007-10-31 | 2007-10-31 | Una vacuna multicomponente o monocomponente para ser utilizada contra la enfermedad de chagas, composiciones farmaceuticas que las contienen, procedimiento para la obtencion del inmunogeno de dichas vacunas y acido nucleico utilizado en dicho procedimiento. |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PA8816401A1 true PA8816401A1 (es) | 2009-09-17 |
Family
ID=40591558
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PA20098816401A PA8816401A1 (es) | 2007-10-31 | 2009-02-19 | Patente de invencion de una vacuna multicomponente o monocomponente para ser utilizada contra la enfermedad de chagas, composiciones farmacéuticas que las contienen, procedimiento para la obtención del inmunógeno que las contienen, procedimiento para |
Country Status (18)
| Country | Link |
|---|---|
| US (3) | US8900598B2 (es) |
| EP (1) | EP2206513B1 (es) |
| AR (1) | AR064593A1 (es) |
| BR (1) | BRPI0805753A2 (es) |
| CA (1) | CA2702534C (es) |
| CO (1) | CO6280407A2 (es) |
| CR (1) | CR11334A (es) |
| DO (1) | DOP2010000083A (es) |
| EC (1) | ECSP10010055A (es) |
| ES (1) | ES2569943T3 (es) |
| GT (1) | GT201000066A (es) |
| HN (1) | HN2010000750A (es) |
| MX (1) | MX2010004626A (es) |
| NI (1) | NI201000071A (es) |
| PA (1) | PA8816401A1 (es) |
| PE (2) | PE20140520A1 (es) |
| UY (1) | UY31451A1 (es) |
| WO (1) | WO2009056965A2 (es) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR064593A1 (es) * | 2007-10-31 | 2009-04-15 | Baeremaecker Barros Carlos De | Una vacuna multicomponente o monocomponente para ser utilizada contra la enfermedad de chagas, composiciones farmaceuticas que las contienen, procedimiento para la obtencion del inmunogeno de dichas vacunas y acido nucleico utilizado en dicho procedimiento. |
| WO2011031317A2 (en) | 2009-09-10 | 2011-03-17 | The Board Of Regents Of The University Of Texas System | Vaccine for control of trypanosoma cruzi infection and chagas disease |
| WO2013011184A2 (es) * | 2011-07-21 | 2013-01-24 | Consejo Superior De Investigaciones Científicas (Csic) | Molécula quimerica util en inmunoterapia frente a la leishmaniosis, que comprende un fragmento de la proteina pfr1 de leishmania infantum con epitopes especificos inmunodominantes |
| US10279023B2 (en) | 2013-09-24 | 2019-05-07 | Board Of Regents, The University Of Texas System | Mucin-associated surface protein as a vaccine against chagas disease |
| US9566320B2 (en) | 2013-09-24 | 2017-02-14 | The Board Of Regents Of The University Of Texas System | Mucin-associated surface protein as vaccine against Chagas disease |
| WO2016209598A1 (en) * | 2015-06-23 | 2016-12-29 | Saint Louis University | Peptides for inducing chagas disease responses |
| BR102021010469A2 (pt) * | 2021-05-28 | 2022-12-13 | Fundação Oswaldo Cruz | Proteína quimérica recombinante, seu uso, e, composição |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU3937593A (en) | 1992-03-25 | 1993-10-21 | New York University | Trans-sialidase and methods of use and making thereof |
| US6875584B1 (en) * | 1999-03-02 | 2005-04-05 | University Of Georgia Research Foundation, Inc. | Prophylactic and therapeutic immunization against protozoan infection and disease |
| US7060676B2 (en) * | 1999-12-20 | 2006-06-13 | Trustees Of Tufts College | T. cruzi-derived neurotrophic agents and methods of use therefor |
| US7780969B2 (en) * | 2005-07-15 | 2010-08-24 | University Of Georgia Research Foundation, Inc. | Trypanosoma cruzi proteome compositions and methods |
| WO2007107488A2 (en) * | 2006-03-17 | 2007-09-27 | Vib Vzw | Vaccine against trypanosoma cruzi infection |
| AR064593A1 (es) * | 2007-10-31 | 2009-04-15 | Baeremaecker Barros Carlos De | Una vacuna multicomponente o monocomponente para ser utilizada contra la enfermedad de chagas, composiciones farmaceuticas que las contienen, procedimiento para la obtencion del inmunogeno de dichas vacunas y acido nucleico utilizado en dicho procedimiento. |
-
2007
- 2007-10-31 AR ARP070104827A patent/AR064593A1/es unknown
-
2008
- 2008-10-30 PE PE2013002770A patent/PE20140520A1/es active IP Right Grant
- 2008-10-30 CA CA2702534A patent/CA2702534C/en not_active Expired - Fee Related
- 2008-10-30 ES ES08844056.5T patent/ES2569943T3/es active Active
- 2008-10-30 WO PCT/IB2008/002923 patent/WO2009056965A2/es active Application Filing
- 2008-10-30 PE PE2008001858A patent/PE20091161A1/es not_active Application Discontinuation
- 2008-10-30 US US12/740,393 patent/US8900598B2/en not_active Expired - Fee Related
- 2008-10-30 EP EP08844056.5A patent/EP2206513B1/en not_active Not-in-force
- 2008-10-30 MX MX2010004626A patent/MX2010004626A/es active IP Right Grant
- 2008-10-31 UY UY31451A patent/UY31451A1/es not_active Application Discontinuation
- 2008-10-31 BR BRPI0805753-2A patent/BRPI0805753A2/pt not_active Application Discontinuation
-
2009
- 2009-02-19 PA PA20098816401A patent/PA8816401A1/es unknown
-
2010
- 2010-03-15 DO DO2010000083A patent/DOP2010000083A/es unknown
- 2010-03-23 GT GT201000066A patent/GT201000066A/es unknown
- 2010-03-24 CR CR11334A patent/CR11334A/es unknown
- 2010-03-26 EC EC2010010055A patent/ECSP10010055A/es unknown
- 2010-04-21 HN HN2010000750A patent/HN2010000750A/es unknown
- 2010-04-26 NI NI201000071A patent/NI201000071A/es unknown
- 2010-05-18 CO CO10058905A patent/CO6280407A2/es unknown
-
2014
- 2014-10-31 US US14/529,454 patent/US9662378B2/en not_active Expired - Fee Related
-
2017
- 2017-04-20 US US15/492,365 patent/US10213500B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| AR064593A1 (es) | 2009-04-15 |
| EP2206513A2 (en) | 2010-07-14 |
| HN2010000750A (es) | 2013-08-19 |
| MX2010004626A (es) | 2010-10-04 |
| WO2009056965A2 (es) | 2009-05-07 |
| NI201000071A (es) | 2010-11-10 |
| US9662378B2 (en) | 2017-05-30 |
| CR11334A (es) | 2010-05-26 |
| ECSP10010055A (es) | 2010-06-29 |
| UY31451A1 (es) | 2009-05-29 |
| US10213500B2 (en) | 2019-02-26 |
| EP2206513B1 (en) | 2016-02-17 |
| DOP2010000083A (es) | 2010-07-15 |
| GT201000066A (es) | 2012-04-03 |
| CA2702534A1 (en) | 2009-05-07 |
| BRPI0805753A2 (pt) | 2012-04-17 |
| US20170290896A1 (en) | 2017-10-12 |
| US8900598B2 (en) | 2014-12-02 |
| WO2009056965A3 (es) | 2009-07-23 |
| ES2569943T3 (es) | 2016-05-13 |
| CA2702534C (en) | 2016-10-18 |
| CO6280407A2 (es) | 2011-05-20 |
| US20150056243A1 (en) | 2015-02-26 |
| PE20091161A1 (es) | 2009-08-28 |
| US20100297186A1 (en) | 2010-11-25 |
| PE20140520A1 (es) | 2014-05-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PA8816401A1 (es) | Patente de invencion de una vacuna multicomponente o monocomponente para ser utilizada contra la enfermedad de chagas, composiciones farmacéuticas que las contienen, procedimiento para la obtención del inmunógeno que las contienen, procedimiento para | |
| BR112016010383A2 (pt) | compostos de pyy seletivos e usos dos mesmos | |
| CL2018003492A1 (es) | Hepatitis b agentes antivirales. | |
| CO2018002060A2 (es) | Compuestos farmacéuticos | |
| BR112017013534A2 (pt) | montagens do adaptador de frasco duplo com adaptador de frasco de medicamento de rápida liberação para utilização correta | |
| AR104984A1 (es) | Compuestos selectivos para pyy y sus usos | |
| BR112017015906A2 (pt) | complexo compreendendo um peptídeo de penetração celular, uma carga e um agonista de peptídeo tlr | |
| BR112015022096A8 (pt) | compostos moduladores de canal de sódio, composição que os compreende e uso dos mesmos | |
| BR112016015422A2 (pt) | formulações de vacina de frasco único | |
| CL2017001961A1 (es) | Vacuna bivalente contra el virus de gripe porcina | |
| PE20190458A1 (es) | Composiciones de neisseria meningitidis y metodos de las mismas | |
| BR112016000563A2 (pt) | Método de preparar uma formulação farmacêutica, método de usar ácido hexanóico e/ou ácido cítrico ou pelo menos um sal dos mesmos, formulação farmacêutica e método de modular ou determinar respostas imunes relacionadas à administração de uma formulação farmacêutica | |
| CO2019000214A2 (es) | Vacuna contra virus de bronquitis infecciosa | |
| DOP2010000188A (es) | Una vacuna de vih que comprende una proteina y un agente estabilizador | |
| BR112017022755A2 (pt) | formulações de glucopiranosil lipídeo a e alérgeno a amendoim para administração sublingual | |
| UY38707A (es) | Nuevos antagonistas cíclicos del receptor b2 de bradiquinina | |
| MA42317B2 (fr) | Composition de vaccin combinée pour administration multiple | |
| BR112016025977A2 (pt) | composições, métodos e utilizações para formulações de papilomavirus humano estábulo estável | |
| BR112015018200A2 (pt) | composição mastigável para administração oral e processo para preparar a mesma | |
| BR112017014849A2 (pt) | Processo para preparação de ácido hialurônico- butirato e uso de um ácido hialurônico-butirato | |
| AR076479A1 (es) | Composiciones farmaceuticas para terapias de mantenimiento que contienen como ingrediente activo un anticuerpo que reconoce el antigeno leucocitario humano (hla) de clase i | |
| AR090095A1 (es) | Preparacion farmaceutica que comprende hormona estimulante del foliculo recombinante | |
| BR112021003425B8 (pt) | Método implementado por computador de planejamento de um tratamento dentário restaurador | |
| BR112016006145A2 (pt) | dispositivo de fixação externa para osteossíntese do ombro | |
| CO6280495A2 (es) | Vacuna que contiene un extracto de proteina ribosoma (rpe) y opcionalmente un adyuvante que estimula las th1 |